XHe-II-053 | 612526-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 英文名称: XHe-II-053
• 英文别名: ethyl-8-ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-carboxylate；ethyl 8-ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate；Ethyl 8-acetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate；Ethyl 12-ethynyl-9-phenyl-2,4,8-triazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene-5-carboxylate；ethyl 8-ethynyl-6-phenyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate
• CAS: 612526-11-1
• 化学式: C₂₂H₁₇N₃O₂
• 分子量: 355.396
• InChiKey: HZYHQJXUEKIREU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  XHe-II-053 在 lithium aluminium tetrahydride 、 potassium carbonate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 17.0h， 生成 5-(8-ethynyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepin-3-yl)oxazole
  参考文献：
  名称：

  Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABA_A) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy

  摘要：

  1,4-Benzodiazepines are used in the treatment of anxiety disorders but have limited long-term use due to adverse effects. HZ-166 (2) has been shown to have anxiolytic-like effects with reduced sedative/ataxic liabilities. A 1,3-oxazole KRM-II-81 (9) was discovered from a series of six bioisosteres with significantly improved pharmacokinetic and pharmacodynamic properties as compared to 2. Oxazole 9 was further characterized and exhibited improved anxiolytic-like effects in a mouse marble burying assay and a rat Vogel conflict test.

  DOI：

  10.1021/acs.jmedchem.6b01332
• 作为产物：
  描述：

  Ethyl 8-trimethylsilylacetylenyl-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate 生成 XHe-II-053
  参考文献：
  名称：

  SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES

  摘要：

  在优选实施方式中，本发明提供了用于抑制、缓解和预防癫痫发作的治疗方法和药物组合物。本发明的优选实施方式进一步涉及使用苯二氮䓬类衍生物的治疗方法和药物组合物，该类衍生物在减少镇静和共济失调副作用的同时提供了抑制、缓解和预防癫痫发作的效果。

  公开号：

  US20100261711A1

文献信息

• Carboxamide GABAa ALPHA2 Modulators
  申请人：Mattson Ronald J.

  公开号：US20090093466A1

  公开（公告）日：2009-04-09

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

  这项发明涵盖了Formula I的化合物，包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的应用。
• [EN] GABA(A) RECEPTOR MODULATORS AND METHODS TO CONTROL AIRWAY HYPERRESPONSIVENESS AND INFLAMMATION IN ASTHMA<br/>[FR] MODULATEURS DU RÉCEPTEUR GABA(A) ET PROCÉDÉS DE CONTRÔLE DE L'HYPERRÉACTIVITÉ DES VOIES RESPIRATOIRES ET DE L'INFLAMMATION DANS L'ASTHME
  申请人：UWM RES FOUNDATION INC

  公开号：WO2018035246A1

  公开（公告）日：2018-02-22

  Pyrrolobenzodiazepines target alpha-4 and alpha-5 GABAA receptors for use in the treatment of airway hyperresponsiveness and inflammation in asthma. Compounds selectively partition to the peripheral compartment and have reduced CNS effects.

  吡咯苯二氮䓬啉靶向α-4和α-5 GABAA受体，用于治疗哮喘中的气道高反应性和炎症。这些化合物选择性地分配到外周区，减少了中枢神经系统的影响。
• Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects
  申请人：Cook M. James

  公开号：US20060003995A1

  公开（公告）日：2006-01-05

  The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.

  本发明提供了使用立体特异性苯二氮卓类衍生物、它们的盐和前药治疗焦虑症或癫痫发作障碍的组合物和方法，该方法具有减少酒精渴望的副作用，同时减少酒精成瘾者的镇静、催眠、肌肉松弛和共济失调副作用。本发明还提供了用于治疗焦虑症和癫痫发作障碍的药物组合物，包括具有化学结构由任何一种I-XXI式表示的化合物、前药或盐，以及一种药学上可接受的载体。
• GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES
  申请人：Cook James M.

  公开号：US20120295892A1

  公开（公告）日：2012-11-22

  Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

  本文描述了α3或α2或α2/α3 GABA能受体亚型选择性配体、药物组合物以及使用这些配体和组合物治疗焦虑症、癫痫和精神分裂症的方法，具有减少镇静和共济失调副作用。在某些实施例中，例如α3或α2或α2/α3 GABA能受体亚型选择性配体不含酯键，因此相对不容易被酯酶水解。
• Anxiolytic agents with reduced sedative and ataxic effects
  申请人：——

  公开号：US20040082573A1

  公开（公告）日：2004-04-29

  Orally active benzodiazepine derivatives and their salts are disclosed. These compounds and their salts have anxiolytic and anticonvulsant activity with reduced sedative/hypnotic/muscle relaxant/ataxic effects.

  本发明公开了口服活性苯二氮卓衍生物及其盐。这些化合物及其盐具有抗焦虑和抗抽搐活性，同时减少了镇静/催眠/肌肉松弛/共济失调的副作用。